Company

AstraZeneca (AZN) · Stockholm Insider

Company desk

AstraZeneca

AZN · XSTO

Health Care

British-Swedish biopharmaceutical company developing prescription medicines across oncology, CVRM, respiratory and rare disease.

On this issuerLeif Johansson · chair Pascal Soriot · CEO Aradhana Sarin · CFO

AstraZeneca PLCISIN GB0009895292LEI PY6ZZQWO2IZFZC3IOL08IR site

Show on Capital →Export evidence pack

Sources healthyNewest data 3m ago

Company identity & filings

Org number: —
Organisation form: —
Registration status: —
Latest annual report: No digital filing ingested

Official registry data · as of — · scheduled, not live

AIAI explanation

What printed

AI-generated, evidence-linked1/4

AstraZeneca 30 dagar: tre insider-köp samma dag och fem kliniska/regulatoriska besked

Under den senaste 30-dagarsperioden rapporterade tre insider (ordförande Michel Demare, CFO Aradhana Sarin och vd Pascal Soriot) öppna marknads-köp i AstraZeneca-aktien den 13 september 2026 enligt Finansinspektionens insider-register. Av transaktionsdetaljerna framgår att Demare köpte 2 500 stamaktier till 121,213296 GBP per aktie; Sarin rapporterade 73 stamaktier med ett noterat pris om 0 GBP (storlek framgår inte av utdraget); Soriots transaktionsdetaljer återges inte i underlaget. Den 15 september publicerades två formella bolagsmeddelanden med titeln 'Director/insider Shareholding' på Nasdaq Nordic. Parallellt kom fem IR-pressmeddelanden: prioriterad granskning (Priority Review) i USA för efzimfotase alfa vid hypofosfatasi för patienter från 2 år (18 september); data för Enhertu i DESTINY-Lung04 med rapporterad PFS på 14,3 månader som första linjes behandling vid HER2-muterad avancerad NS…

OBSMarket observation

Price & volume

AZN · daily bars · evidence markers

Public source

HISTORICAL BEHAVIOUR

Prepared print

T−60 → T0 → T+32

Loading replay…

THIS PRINT · HISTORICAL OUTCOMES · NOT A FORECAST

Aradhana Sarin · buy · 2026-08-16

+0,6 %

T+1 abs · +0,9 % vs OMX

+6,6 %

T+5 abs · +6,0 % vs OMX

+3,9 %

T+20 abs · +4,5 % vs OMX

—

T+60 abs

—

T+120 abs

Yahoo OHLC (Tier-3 / unofficial) when that is the bar source — not a licensed close.

Event replay uses prepared studies and bars already on the desk — not a forecast.

SAME-CLASS COHORT · NOT A FORECAST

n=721

Leadership buys · tracked universe

+0,5 % median T+5 vs OMXS30

+2,4 % median T+20 vs OMXS30

FACTSSourced facts

Announcements & filings

Disclosed filings and registers — not inferred

AstraZeneca announces strategic equity investment and clinical collaboration with Summit Therapeutics to advance leading ADC combination strategy in cancer
Announcement11h agoIssuer IR via MFN (press rooms)Source
AstraZeneca: Perioperative Imfinzi plus neoadjuvant enfortumab vedotin granted Priority Review in the US for patients with muscle-invasive bladder cancer
Announcement4d agoIssuer IR via MFN (press rooms)Source
AstraZeneca: Alexion advances pioneering leadership in gMG care with data at 2026 AANEM Annual Meeting and MGFA Scientific Session
Announcement5d agoIssuer IR via MFN (press rooms)Source
AstraZeneca: Trixeo approved in the EU for the maintenance treatment of asthma
Announcement6d agoIssuer IR via MFN (press rooms)Source
Klygefa recommended for EU approval by CHMP
Announcement8d agoNasdaq Nordic company announcementsSource
Enhertu recommended for approval in EU in early BC
Announcement8d agoNasdaq Nordic company announcementsSource
AstraZeneca: Klygefa (gefurulimab) recommended for approval in the EU by CHMP for the treatment of adults with generalised myasthenia gravis (gMG)
Announcement11d agoIssuer IR via MFN (press rooms)Source
Director/PDMR Shareholding
Announcement11d agoNasdaq Nordic company announcementsSource
AstraZeneca: Efzimfotase alfa granted Priority Review in the US as treatment for patients with hypophosphatasia aged 2 years and older
Announcement11d agoIssuer IR via MFN (press rooms)Source
Director/PDMR Shareholding
Announcement14d agoNasdaq Nordic company announcementsSource
Director/PDMR Shareholding
Announcement14d agoNasdaq Nordic company announcementsSource
AstraZeneca: Enhertu demonstrated a median progression-free survival of 14.3 months as 1st-line therapy in patients with HER2-mutant advanced non-small cell lung cancer in DESTINY-Lung04 Phase III trial
Announcement15d agoIssuer IR via MFN (press rooms)Source
AstraZeneca: Tagrisso demonstrated unprecedented eight-year landmark survival in early-stage EGFR-mutated lung cancer in ADAURA Phase III trial
Announcement15d agoIssuer IR via MFN (press rooms)Source
AstraZeneca: Imfinzi+Imdelltra improved OS in small cell lung
Announcement21d agoIssuer IR via MFN (press rooms)Source
AstraZeneca: Tozorakimab demonstrated statistically significant and highly clinically meaningful reduction in COPD exacerbations in OBERON and TITANIA Phase III trials
Announcement21d agoIssuer IR via MFN (press rooms)Source
AstraZeneca: Etcamah in combination with a CDK4/6 inhibitor approved in the US for 1st-line advanced HR-positive breast cancer
Announcement22d agoIssuer IR via MFN (press rooms)Source
Admission of Further Securities to Trading
Announcement28d agoNasdaq Nordic company announcementsSource
Total Voting Rights
Announcement28d agoNasdaq Nordic company announcementsSource
Admission to Trading - €2.55 billion bond offering
Announcement28d agoNasdaq Nordic company announcementsSource
AstraZeneca: Enhertu plus pertuzumab approved in the EU as first new regimen in more than a decade for the 1st-line treatment of patients with HER2-positive metastatic breast cancer
Announcement28d agoIssuer IR via MFN (press rooms)Source
Directorate change
Announcement28d agoNasdaq Nordic company announcementsSource
AstraZeneca completes global license agreement for oral EGFR inhibitor Zegfrovy for lung cancer
Announcement28d agoIssuer IR via MFN (press rooms)Source
AstraZeneca: Tagrisso plus Orpathys demonstrated statistically significant and highly clinically meaningful improvement in progression-free survival in 1st-line MET-overexpressing EGFR-mutated lung cancer
Announcement28d agoIssuer IR via MFN (press rooms)Source
Tezspire CROSSING trial met primary endpoints
Announcement2026-08-27Nasdaq Nordic company announcementsSource
AstraZeneca prices a €2.55 billion bond offering
Announcement2026-08-25Nasdaq Nordic company announcementsSource

FACTSSourced facts

People

Board · management · open first, ended tagged. PDMR related parties omitted.

Management

Pascal SoriotCEO
Chief Executive Officer (CEO)/Managing Directory
2012-10-01 → open
French businessman; CEO of AstraZeneca
high confidence
Aradhana SarinCFO
Chief Financial Officer (CFO)
high confidence

Board

Themes

No theme exposure detected.

Related companies

Sectravia Health Care peer

Explore

Open in Network →All intelligence for AstraZeneca →

AstraZeneca

AstraZeneca 30 dagar: tre insider-köp samma dag och fem kliniska/regulatoriska besked

Price & volume

Has this happened before?

Prior disclosed clusters

What changed

AstraZeneca announces strategic equity investment and clinical collaboration with Summit Therapeutics to advance leading ADC combination strategy in cancer

AstraZeneca: Perioperative Imfinzi plus neoadjuvant enfortumab vedotin granted Priority Review in the US for patients with muscle-invasive bladder cancer

Peer register lanes

Disclosed capital — separate registers

Threshold film · Flaggning

Reported insider transactions

Announcements & filings

People

Themes

Related companies

Explore

Upcoming sourced days

In tension

AstraZeneca: Alexion advances pioneering leadership in gMG care with data at 2026 AANEM Annual Meeting and MGFA Scientific Session

AstraZeneca: Trixeo approved in the EU for the maintenance treatment of asthma

Klygefa recommended for EU approval by CHMP

Enhertu recommended for approval in EU in early BC

AstraZeneca: Klygefa (gefurulimab) recommended for approval in the EU by CHMP for the treatment of adults with generalised myasthenia gravis (gMG)

Director/PDMR Shareholding

AstraZeneca: Efzimfotase alfa granted Priority Review in the US as treatment for patients with hypophosphatasia aged 2 years and older

Director/PDMR Shareholding

Director/PDMR Shareholding

AstraZeneca: Enhertu demonstrated a median progression-free survival of 14.3 months as 1st-line therapy in patients with HER2-mutant advanced non-small cell lung cancer in DESTINY-Lung04 Phase III trial

AstraZeneca: Tagrisso demonstrated unprecedented eight-year landmark survival in early-stage EGFR-mutated lung cancer in ADAURA Phase III trial

Michel Demare (Chairman of the Board of Directors) reported purchase

Aradhana Sarin (Chief Financial Officer (CFO)) reported purchase